Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
Interdisciplinary Care: The Health Care Team-II
Dementia
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jun 15, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Katherine W Turk1, Mark D Knobel1, Alexandra Nothern1
1Neurology Service (KWT, MDK, GF, HN, BC, DCA, AC, BVR, AEB); Center for Translational Cognitive Neuroscience (KWT, MDK, GF, HN, BC, DCA, AC, AEB), VA Boston Healthcare System; Neurology Service (KWT, AEB), Alzheimer's Disease Research Center, Boston University School of Medicine; Geriatrics Service (AN); Radiology Service (AM); Nursing Service (VC, NP); and Clinical Pharmacy Service (CW, LMV, JR, LT), VA Boston Healthcare System, Boston, MA.
New amyloid-targeting immunotherapies like lecanemab offer Alzheimer disease treatment promise but carry risks. This study shares resources developed for safe lecanemab infusion implementation and monitoring at a major medical center.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: